KRT18 and metabolic dysfunction-associated steatohepatitis: The plasma cytokeratin 18 (CK18) fragment level, a marker of hepatocyte apoptosis, has been extensively evaluated in steatohepatitis, while its limited sensitivity of 58% (51–65%) makes it inadequate as a screening test for staging NASH [32,33].